(ALNY) Alnylam Pharmaceuticals - Overview
Stock: Rna Therapeutics, Amyloidosis Drugs, Cardiometabolic Agents
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 48.0% |
| Relative Tail Risk | -15.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | 4.49 |
| Character TTM | |
|---|---|
| Beta | 0.881 |
| Beta Downside | 0.955 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.28% |
| CAGR/Max DD | 0.42 |
Description: ALNY Alnylam Pharmaceuticals January 29, 2026
Alnylam Pharmaceuticals (NASDAQ: ALNY) is a U.S. biotech that builds its business on RNA-interference (RNAi) therapeutics. Its commercial portfolio includes ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm is advancing a broad pipeline of RNAi candidates across multiple disease areas, with at least nine programs in late-stage trials (e.g., vutrisiran for ATTR-cardiomyopathy, Fitusiran for hemophilia, and cemdisiran for Myasthenia Gravis).
The pipeline also contains early-stage assets targeting hypertension (Zilebesiran), metabolic-associated steatohepatitis (Rapirosiran), type 2 diabetes (ALN-4324), dyslipidemia (ALN-APOC3), and neurodegenerative disorders such as Huntington’s disease (ALN-HTT02). Alnylam leverages a network of collaborations with major pharma partners-including Regeneron, Roche, Sanofi, Novartis, and Ionis-to co-develop and commercialize RNAi drugs, which helps diversify risk and expand market reach.
As of the Q4 2023 earnings release (Feb 2024), Alnylam reported revenue of $1.02 billion, a 27 % YoY increase driven primarily by Leqvio sales, while R&D expense rose 15 % to $560 million, reflecting late-stage trial activity. The company’s cash runway extends beyond 2026 at current burn rates, and its market capitalization sits near $12 billion, positioning it among the larger RNAi players. Industry analysts note that the RNAi market is projected to grow at a CAGR of ~12 % through 2030, supported by expanding FDA approvals and payer acceptance of gene-silencing therapies-key macro drivers that could amplify Alnylam’s upside if its late-stage candidates succeed.
For a deeper quantitative assessment of how these catalysts translate into valuation risk/reward, you may want to explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 43.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 4.18 > 1.0 |
| NWC/Revenue: 74.68% < 20% (prev 101.9%; Δ -27.23% < -1%) |
| CFO/TA 0.05 > 3% & CFO 265.9m > Net Income 43.6m |
| Net Debt (1.28b) to EBITDA (186.5m): 6.88 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.3m) vs 12m ago 6.81% < -2% |
| Gross Margin: 83.99% > 18% (prev 0.85%; Δ 8313 % > 0.5%) |
| Asset Turnover: 70.89% > 50% (prev 49.82%; Δ 21.07% > 0%) |
| Interest Coverage Ratio: 0.80 > 6 (EBITDA TTM 186.5m / Interest Expense TTM 162.3m) |
Altman Z'' -3.01
| A: 0.49 (Total Current Assets 3.95b - Total Current Liabilities 1.56b) / Total Assets 4.85b |
| B: -1.48 (Retained Earnings -7.16b / Total Assets 4.85b) |
| C: 0.03 (EBIT TTM 130.2m / Avg Total Assets 4.53b) |
| D: -1.56 (Book Value of Equity -7.18b / Total Liabilities 4.62b) |
| Altman-Z'' Score: -3.01 = D |
Beneish M -1.91
| DSRI: 1.78 (Receivables 964.8m/353.9m, Revenue 3.21b/2.09b) |
| GMI: 1.02 (GM 83.99% / 85.37%) |
| AQI: 1.22 (AQ_t 0.04 / AQ_t-1 0.03) |
| SGI: 1.53 (Revenue 3.21b / 2.09b) |
| TATA: -0.05 (NI 43.6m - CFO 265.9m) / TA 4.85b) |
| Beneish M-Score: -1.91 (Cap -4..+1) = B |
What is the price of ALNY shares?
Over the past week, the price has changed by -2.93%, over one month by -19.25%, over three months by -25.50% and over the past year by +17.94%.
Is ALNY a buy, sell or hold?
- StrongBuy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ALNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 477.2 | 45.4% |
| Analysts Target Price | 477.2 | 45.4% |
| ValueRay Target Price | 335.7 | 2.3% |
ALNY Fundamental Data Overview February 03, 2026
P/E Forward = 47.619
P/S = 13.9132
P/B = 195.8825
P/EG = -0.49
Revenue TTM = 3.21b USD
EBIT TTM = 130.2m USD
EBITDA TTM = 186.5m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 160.4m USD (from shortTermDebt, last quarter)
Debt = 2.77b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.28b USD (from netDebt column, last quarter)
Enterprise Value = 44.71b USD (44.66b + Debt 2.77b - CCE 2.72b)
Interest Coverage Ratio = 0.80 (Ebit TTM 130.2m / Interest Expense TTM 162.3m)
EV/FCF = 202.0x (Enterprise Value 44.71b / FCF TTM 221.4m)
FCF Yield = 0.50% (FCF TTM 221.4m / Enterprise Value 44.71b)
FCF Margin = 6.90% (FCF TTM 221.4m / Revenue TTM 3.21b)
Net Margin = 1.36% (Net Income TTM 43.6m / Revenue TTM 3.21b)
Gross Margin = 83.99% ((Revenue TTM 3.21b - Cost of Revenue TTM 514.0m) / Revenue TTM)
Gross Margin QoQ = 84.21% (prev 81.52%)
Tobins Q-Ratio = 9.22 (Enterprise Value 44.71b / Total Assets 4.85b)
Interest Expense / Debt = 1.60% (Interest Expense 44.4m / Debt 2.77b)
Taxrate = 21.0% (US default 21%)
NOPAT = 102.9m (EBIT 130.2m * (1 - 21.00%))
Current Ratio = 2.54 (Total Current Assets 3.95b / Total Current Liabilities 1.56b)
Debt / Equity = 11.86 (Debt 2.77b / totalStockholderEquity, last quarter 233.9m)
Debt / EBITDA = 6.88 (Net Debt 1.28b / EBITDA 186.5m)
Debt / FCF = 5.80 (Net Debt 1.28b / FCF TTM 221.4m)
Total Stockholder Equity = 166.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.96% (Net Income 43.6m / Total Assets 4.85b)
RoE = 26.13% (Net Income TTM 43.6m / Total Stockholder Equity 166.8m)
RoCE = 10.79% (EBIT 130.2m / Capital Employed (Equity 166.8m + L.T.Debt 1.04b))
RoIC = 8.60% (NOPAT 102.9m / Invested Capital 1.20b)
WACC = 8.70% (E(44.66b)/V(47.44b) * Re(9.16%) + D(2.77b)/V(47.44b) * Rd(1.60%) * (1-Tc(0.21)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.57%
[DCF Debug] Terminal Value 67.11% ; FCFF base≈139.2m ; Y1≈91.4m ; Y5≈41.7m
Fair Price DCF = N/A (negative equity: EV 726.8m - Net Debt 1.28b = -556.3m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 72.77 | EPS CAGR: 39.58% | SUE: -2.44 | # QB: 0
Revenue Correlation: 90.99 | Revenue CAGR: 52.20% | SUE: 2.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.34 | Chg30d=+0.140 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=10.59 | Chg30d=-0.595 | Revisions Net=+0 | Growth EPS=+121.0% | Growth Revenue=+45.7%